Biocryst Pharmaceuticals (BCRX) 8.34 $BCRX
Global Lymphoblastic Lymphoma Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cl8k6m/lymphoblastic) has announced the addition of the "Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014" report to their offering. Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Lymphoblastic Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lymphoblastic Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lymphoblastic Lymphoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Lymphoblastic Lymphoma Therapeutics Clinical Trials - Novartis AG - GlaxoSmithKline plc - Pfizer Inc. - Sanofi - Jazz Pharmaceuticals plc - Bristol-Myers Squibb Company - AstraZeneca PLC - Eisai Inc. - BioCryst Pharmaceuticals, Inc. - Amgen Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - The University of Texas M. D. Anderson Cancer Center - Children's Oncology Group - Memorial Sloan Kettering Cancer Center - Case Comprehensive Cancer Center - St. Jude Children's Research Hospital, Inc. - Johann Wolfgang Goethe University Hospitals - Stanford University - University of Washington For more information visit http://www.researchandmarkets.com/research/cl...phoblastic
'Mad Money' Lightning Round: Hess Is Undervalued
at The Street - Sat Apr 05, 5:00AM CDT
Cramer would go with Salesforce.com but avoid BioCryst Pharmaceuticals.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Apr 04, 7:31PM CDT
Caution, not aggression, will be the rule next week, Cramer says.
Biotech Stocks Technical Review -- Research on BioCryst Pharma, Spectrum Pharma, BioMarin Pharma, and Vertex Pharma
PR Newswire - Wed Mar 26, 10:55AM CDT
On Tuesday, March 25, 2014, the NASDAQ Composite ended at 4,234.27, up 0.19%, the Dow Jones Industrial Average advanced 0.56% to 16,367.88, and the S&P 500 closed at 1,865.62, up 0.44%. The gains were broad based as nine out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 671.69, up 0.83%, while the same has fallen by 1.64% in the last one month. Investor-Edge has initiated coverage on the following equities: BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free technical research on BCRX, SPPI, BMRN, and VRTX can be downloaded upon signing up at:
Trade-Ideas: Biocryst Pharmaceuticals (BCRX) Is Today's "Dead Cat Bounce" Stock
at The Street - Mon Mar 10, 8:47AM CDT
Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a "dead cat bounce" (down big yesterday but up big today) candidate
BioCryst Announces Nature Publication Demonstrating Efficacy of BCX4430 in a Non-Human Primate Model of Filovirus Infection
GlobeNewswire - Mon Mar 03, 5:30AM CST
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the online publication in the journal Nature of extensive laboratory and nonclinical characterizations of BCX4430, including efficacy results in animal models of infection with Marburg virus and Ebola virus, two highly virulent pathogens responsible for viral hemorrhagic fever diseases. The Nature online publication, "Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430," represents the first report of protection of non-human primates from filovirus disease by a small molecule drug, and describes efficacy results generated from an ongoing collaboration between scientists at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and BioCryst.
BioCryst Presents BCX4161 Phase 1 Trial and Kallikrein Inhibition Assay Results
GlobeNewswire - Sat Mar 01, 10:58AM CST
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced the presentation of two scientific posters today at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Diego describing phase 1 clinical trial results for BioCryst's potent and selective oral kallikrein inhibitor, BCX4161, together with details of the Company's plasma kallikrein inhibition assay. BCX4161 is currently being evaluated in a Phase 2 clinical trial, OPuS-1, as a potential treatment for the prevention of hereditary angioedema (HAE) attacks.
Avanir Pharmaceuticals (AVNR) Jumps: Stock Moves 11.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:46AM CST
Avanir Pharmaceuticals was a big mover last session, with shares rising nearly 12%.
BioCryst Pharmaceuticals Q4 Loss Shrinks 51% on Higher Collaborative Revenue
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 26, 11:17AM CST
Following yesterday's double-digit gains after the Food and Drug Administration accepted its new drug application (NDA) filing for peramivir as a treatment for influenza, BioCryst Pharmaceuticals hoped to keep the good times rolling with the...
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Rises 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 8:39AM CST
BioCryst Pharmaceuticals, Inc. was a big mover last session, as its shares rose almost 11% on the day.
Infinity Pharmaceuticals (INFI) Jumps: Stock Adds 15.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 7:51AM CST
Infinity Pharmaceuticals, Inc. was a big mover last session, as its shares rose almost 16% on the day.
BioCryst Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Wed Feb 26, 5:51AM CST
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the fourth quarter and full year ended December 31, 2013.
Why BioCryst Pharmaceuticals, Inc. Shares Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 25, 1:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of BioCryst Pharmaceuticals , a...
Today's Biggest Biotech Stories: BioCryst, Verastem, and InterMune
Leo Sun, The Motley Fool - Motley Fool - Tue Feb 25, 8:35AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a...
RXi Pharmaceuticals (RXII) Jumps: Stock Adds 28.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 7:51AM CST
RXi Pharmaceuticals Corporation was a big mover last session, as its shares rose almost 29% on the day.
BioCryst Announces Peramivir NDA Acceptance by the FDA
GlobeNewswire - Tue Feb 25, 5:45AM CST
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for intravenous (i.v.) peramivir that was submitted to the FDA in December 2013. The FDA assigned the NDA a standard review time, resulting in a PDUFA (Prescription Drug User Fee Act) action date of December 23, 2014. The FDA has informed BioCryst that at this time, it does not plan to hold an Advisory Committee review of the NDA.
Today's Biggest Biotech Stories: Antares Pharma Inc., BioCryst Pharmaceuticals Inc., and Raptor Phar
George Budwell, The Motley Fool - Motley Fool - Thu Feb 20, 9:02AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! It's time to check in...
Ackroo launches Ackroo3 - The next generation Gift Card and Loyalty Platform
CNW Group - Thu Feb 20, 7:00AM CST
Ackroo's expands the reach of its gift card and loyalty rewards solutions
BioCryst to Present at Three Upcoming Investor Conferences
GlobeNewswire - Thu Feb 20, 6:30AM CST
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's clinical programs at the following investor conferences:
Lannett (ACO) Worth Watching: Stock Rises 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:25AM CST
Lannett Company was a big mover last session, with shares rising over 6%.
Global Lymphoblastic Lymphoma Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cl8k6m/lymphoblastic) has announced the addition of the "Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014" report to their offering. Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014" provides data on the Lymphoblastic Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lymphoblastic Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lymphoblastic Lymphoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Lymphoblastic Lymphoma Therapeutics Clinical Trials - Novartis AG - GlaxoSmithKline plc - Pfizer Inc. - Sanofi - Jazz Pharmaceuticals plc - Bristol-Myers Squibb Company - AstraZeneca PLC - Eisai Inc. - BioCryst Pharmaceuticals, Inc. - Amgen Inc. Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - Fred Hutchinson Cancer Research Center - The University of Texas M. D. Anderson Cancer Center - Children's Oncology Group - Memorial Sloan Kettering Cancer Center - Case Comprehensive Cancer Center - St. Jude Children's Research Hospital, Inc. - Johann Wolfgang Goethe University Hospitals - Stanford University - University of Washington For more information visit http://www.researchandmarkets.com/research/cl...phoblastic
'Mad Money' Lightning Round: Hess Is Undervalued
at The Street - Sat Apr 05, 5:00AM CDT
Cramer would go with Salesforce.com but avoid BioCryst Pharmaceuticals.
Jim Cramer's 'Mad Money' Recap: Next Week's Game Plan
at The Street - Fri Apr 04, 7:31PM CDT
Caution, not aggression, will be the rule next week, Cramer says.
Biotech Stocks Technical Review -- Research on BioCryst Pharma, Spectrum Pharma, BioMarin Pharma, and Vertex Pharma
PR Newswire - Wed Mar 26, 10:55AM CDT
On Tuesday, March 25, 2014, the NASDAQ Composite ended at 4,234.27, up 0.19%, the Dow Jones Industrial Average advanced 0.56% to 16,367.88, and the S&P 500 closed at 1,865.62, up 0.44%. The gains were broad based as nine out of 10 sectors ended the session in positive. The S&P 500 Health Care Sector Index finished the day at 671.69, up 0.83%, while the same has fallen by 1.64% in the last one month. Investor-Edge has initiated coverage on the following equities: BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX). Free technical research on BCRX, SPPI, BMRN, and VRTX can be downloaded upon signing up at:
Trade-Ideas: Biocryst Pharmaceuticals (BCRX) Is Today's "Dead Cat Bounce" Stock
at The Street - Mon Mar 10, 8:47AM CDT
Trade-Ideas LLC identified Biocryst Pharmaceuticals (BCRX) as a "dead cat bounce" (down big yesterday but up big today) candidate
BioCryst Announces Nature Publication Demonstrating Efficacy of BCX4430 in a Non-Human Primate Model of Filovirus Infection
GlobeNewswire - Mon Mar 03, 5:30AM CST
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the online publication in the journal Nature of extensive laboratory and nonclinical characterizations of BCX4430, including efficacy results in animal models of infection with Marburg virus and Ebola virus, two highly virulent pathogens responsible for viral hemorrhagic fever diseases. The Nature online publication, "Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430," represents the first report of protection of non-human primates from filovirus disease by a small molecule drug, and describes efficacy results generated from an ongoing collaboration between scientists at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and BioCryst.
BioCryst Presents BCX4161 Phase 1 Trial and Kallikrein Inhibition Assay Results
GlobeNewswire - Sat Mar 01, 10:58AM CST
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced the presentation of two scientific posters today at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Diego describing phase 1 clinical trial results for BioCryst's potent and selective oral kallikrein inhibitor, BCX4161, together with details of the Company's plasma kallikrein inhibition assay. BCX4161 is currently being evaluated in a Phase 2 clinical trial, OPuS-1, as a potential treatment for the prevention of hereditary angioedema (HAE) attacks.
Avanir Pharmaceuticals (AVNR) Jumps: Stock Moves 11.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 8:46AM CST
Avanir Pharmaceuticals was a big mover last session, with shares rising nearly 12%.
BioCryst Pharmaceuticals Q4 Loss Shrinks 51% on Higher Collaborative Revenue
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 26, 11:17AM CST
Following yesterday's double-digit gains after the Food and Drug Administration accepted its new drug application (NDA) filing for peramivir as a treatment for influenza, BioCryst Pharmaceuticals hoped to keep the good times rolling with the...
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Rises 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 8:39AM CST
BioCryst Pharmaceuticals, Inc. was a big mover last session, as its shares rose almost 11% on the day.
Infinity Pharmaceuticals (INFI) Jumps: Stock Adds 15.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 7:51AM CST
Infinity Pharmaceuticals, Inc. was a big mover last session, as its shares rose almost 16% on the day.
BioCryst Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Wed Feb 26, 5:51AM CST
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the fourth quarter and full year ended December 31, 2013.
Why BioCryst Pharmaceuticals, Inc. Shares Spiked Higher
Sean Williams, The Motley Fool - Motley Fool - Tue Feb 25, 1:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of BioCryst Pharmaceuticals , a...
Today's Biggest Biotech Stories: BioCryst, Verastem, and InterMune
Leo Sun, The Motley Fool - Motley Fool - Tue Feb 25, 8:35AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a...
RXi Pharmaceuticals (RXII) Jumps: Stock Adds 28.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 7:51AM CST
RXi Pharmaceuticals Corporation was a big mover last session, as its shares rose almost 29% on the day.
BioCryst Announces Peramivir NDA Acceptance by the FDA
GlobeNewswire - Tue Feb 25, 5:45AM CST
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for intravenous (i.v.) peramivir that was submitted to the FDA in December 2013. The FDA assigned the NDA a standard review time, resulting in a PDUFA (Prescription Drug User Fee Act) action date of December 23, 2014. The FDA has informed BioCryst that at this time, it does not plan to hold an Advisory Committee review of the NDA.
Today's Biggest Biotech Stories: Antares Pharma Inc., BioCryst Pharmaceuticals Inc., and Raptor Phar
George Budwell, The Motley Fool - Motley Fool - Thu Feb 20, 9:02AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! It's time to check in...
Ackroo launches Ackroo3 - The next generation Gift Card and Loyalty Platform
CNW Group - Thu Feb 20, 7:00AM CST
Ackroo's expands the reach of its gift card and loyalty rewards solutions
BioCryst to Present at Three Upcoming Investor Conferences
GlobeNewswire - Thu Feb 20, 6:30AM CST
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company's clinical programs at the following investor conferences:
Lannett (ACO) Worth Watching: Stock Rises 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 8:25AM CST
Lannett Company was a big mover last session, with shares rising over 6%.
